Susan G. Komen® Chicago held their first MBC Conference March 8, 2018 with about 200 individuals attending in person or via livestream. The conference included a keynote address from Komen Scholar and Johns Hopkins researcher Dr. Ben Ho Park with breakouts on TNBC, ER+ and HER2+ MBC; a MBC patient panel discussion and Q&A session.
SHARE is working with a focus group of women living with metastatic disease to create an app that will help them identify their treatment goals and help their doctors better understand who they are as people. Stay tuned for its release later this year!
Researchers in clinical oncology and other domains generally focus on results encompassing a statistical mean with little attention to patients undergoing investigational or standard therapies who respond considerably better or worse than the norm.
What proportion of MBC patients are de novo vs recurrent? Currently, the Surveillance, Epidemiology and End Results Program, or SEER, provides extensive information regarding cancer diagnosis and some data regarding primary treatment and survival, but it does not collect information on metastatic cancer recurrence.
NEW YORK, Oct 27, 2017 /PRNewswire/ — A retrospective analysis, reported in the journal Breast Cancer Research and Treatment, of more than 8,189 women with invasive breast cancer and 1,158 women diagnosed with metastatic breast cancer (MBC) between 1990 and 2010 identified differences in tumor characteristics and survival due to breast cancer in women diagnosed with de
